Development of PARP Inhibitors in Targeting Castration-Resistant Prostate Cancer

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Prostate cancer exhibits genetic heterogeneity, with a subset of tumors featuring DNA damage and repair (DDR) gene alterations.
• These DDR alterations, arising from germline or somatic events, are more prevalent in high-grade and advanced prostate cancer.
• Homologous recombination (HR) pathway gene alterations correlate with PARP inhibitor sensitivity, as seen in breast and ovarian cancers.

Purpose of the Study:

• To review the current development of PARP inhibitors in prostate cancer treatment.
• To highlight the role of biomarkers in identifying patients likely to benefit from PARP inhibition.
• To discuss potential combination therapy strategies involving PARP inhibitors.

Main Methods:

• Review of recent randomized trials in metastatic castration-resistant prostate cancer (mCRPC).
• Analysis of studies investigating PARP inhibitors in biomarker-selected and unselected mCRPC populations.
• Examination of ongoing trials in earlier stages of prostate cancer with DDR gene alterations.

Main Results:

• Randomized trials confirm the benefit of PARP inhibitors in advanced mCRPC patients with HR gene alterations.
• PARP inhibitors are being investigated in first-line mCRPC and earlier disease states.
• Biomarker selection is crucial for identifying patient populations responsive to PARP inhibitors.

Conclusions:

• PARP inhibitors represent a significant therapeutic advance for a subset of prostate cancer patients with DDR alterations.
• Further research is focused on optimizing PARP inhibitor use through biomarker development and combination therapies.
• The application of PARP inhibitors is expanding to earlier stages of prostate cancer, guided by genetic profiling.